This summer
pemvidutide entered phase 3 last month — but the july data changed what that means
Altimmune's once-weekly injectable peptide entered its registrational Phase 3 trial for metabolic dysfunction-associated steatohepatitis — MASH, the liver disease formerly called NASH — on August 3, 2026. The [PERFORMA trial](https://clinicaltrials.gov/study/NCT07795164) is a global randomized, double-blind, placebo-controlled study designed to support accelerated approval, enrolling roughly 990 patients with confirmed liver fibrosis. That was the story Altimmune had been building toward all year: an FDA Breakthrough Therapy designation in January, 48-week IMPACT Phase 2b results presented at EASL in spring, and a Phase 3 initiation before summer's end. What arrived five days before PERFORMA launched was the other story. On July 28, 2026, Altimmune [announced positive topline results from the RECLAIM Phase 2 trial](https://www.globenewswire.com/news-release/2026/07/28/3334113/0/en/altimmune-announces-positive-topline-results-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder.html) — a study testing pemvidutide in alcohol use disorder. The headline finding: 64.4% of treated patients achieved a two-level reduction in WHO alcohol risk categories, versus 34.8% on placebo. The p-value was 0.0014. A GLP-1/glucagon peptide designed to treat liver disease had just posted statistically significant results in a disease primarily about behavior and reward. September 2026 is the first month most people outside the drug development world are absorbing both of those facts together.
The actual molecule
a balanced 1-to-1 glp-1 and glucagon receptor agonist — two different signals from one weekly injection
Pemvidutide is classified as a balanced dual agonist: it activates GLP-1 receptors and glucagon receptors at roughly equal potency — a 1:1 ratio that distinguishes it from candidates that heavily favor one receptor over the other. [PubMed literature on pemvidutide](https://pubmed.ncbi.nlm.nih.gov/?term=pemvidutide) traces the pharmacodynamic rationale: GLP-1 receptor activation suppresses appetite and slows gastric emptying, while glucagon receptor activation raises resting energy expenditure and promotes fat metabolism in the liver specifically. In the context of MASH — a disease driven by excess fat accumulation and inflammatory damage in the liver — those two mechanisms are complementary by design. The GLP-1 side addresses caloric intake and insulin sensitivity; the glucagon side targets hepatic fat oxidation, the organ the disease damages most directly. That liver specificity is the pharmacological reason MASH, not general obesity, became the primary regulatory target. The alcohol use disorder biology sits in a different part of the mechanistic story — one that has less to do with glucagon signaling and more to do with how GLP-1 receptor activity influences dopamine reward circuitry in the brain, a relationship that has been accumulating evidence since the early 2020s.
The next-wave pitch
the investment narrative was mash and weight loss — alcohol use disorder was not in the forecast
Pemvidutide's public profile in 2026 is built primarily around MASH positioning, the FDA rare disease designation pathway, and the general enthusiasm surrounding multi-agonist metabolic drugs that can claim something beyond what semaglutide or tirzepatide already offer. That positioning is legitimate: MASH affects millions of adults and approved therapeutic options remain limited, which is part of why Breakthrough Therapy Designation signals the agency believes early evidence suggests meaningful improvement over existing therapy. The weight loss numbers from IMPACT — roughly 7.5% at 48 weeks — are not in the same category as the 22-25% figures from tirzepatide or CagriSema. That was always fine because MASH is a liver fibrosis story, not a weight loss competition. What the RECLAIM data introduced in late July is harder to categorize for audiences expecting a standard metabolic drug narrative. A GLP-1/glucagon peptide built for liver fat had just posted statistically significant reductions in heavy alcohol drinking — a finding that moves the conversation into addiction pharmacology, reward biology, and a class of claim that metabolic peptides have not previously been asked to make. Most wellness coverage and peptide community discussion has not yet caught up to either the MASH Phase 3 or the AUD Phase 2 findings.
What the data says
breakthrough designation for mash, 48-week antifibrotic signal, and an aud trial that hit its primary endpoint
The IMPACT Phase 2b trial produced the evidence base for the PERFORMA Phase 3 registration study. At 48 weeks, pemvidutide showed statistically significant improvements in liver fat content and markers associated with fibrosis resolution — results Altimmune presented at the European Association for the Study of the Liver conference in spring 2026. The FDA January 2026 Breakthrough Therapy Designation is a formal regulatory acknowledgment that early MASH data warrants accelerated development collaboration with the agency. The [PERFORMA Phase 3 registration on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07795164) shows two parallel cohorts — roughly 990 biopsy-confirmed patients for accelerated approval, plus 800 patients with non-invasive fibrosis confirmation — with a primary endpoint of MASH resolution and fibrosis improvement at 52 weeks and a final outcomes readout anticipated in 2029. The RECLAIM results, released July 28, address a separate question. Pemvidutide 2.4 mg reduced heavy drinking days by a statistically significant margin versus placebo, with a p-value of 0.0014. Forty-two percent of treated patients achieved zero heavy drinking days during weeks 21 through 24, compared to 17% on placebo. Body weight fell 9.1% in the treated group at 24 weeks, which leaves open the question of how much of the alcohol behavior change was pharmacological, secondary to weight change, or some interaction of both. [FDA guidance on the GLP-1 drug class](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) frames the broader regulatory context for this category of investigational peptide. Altimmune is now pursuing an End-of-Phase 2 meeting with the FDA based on the RECLAIM results.
Early human — PeptideFactCheck stance
interesting enough to watch — the mash and aud signals are real, but the labels are years and multiple trials away
Pemvidutide holds PeptideFactCheck's Early human tier: interesting enough to watch, too early for broad certainty. The drug has more clinical infrastructure than most investigational peptides in the current conversation — a Phase 3 trial now actively enrolling, Phase 2 evidence across two distinct disease populations, FDA Breakthrough Therapy designation, and a molecular mechanism that connects liver fat metabolism, weight regulation, and reward-related behavior in ways that keep generating unexpected data. What it does not have is an approved label, long-term safety data in any target population, or a resolved understanding of how its GLP-1 and glucagon receptor systems interact to produce the AUD signal specifically. A third program, the RESTORE trial in alcohol-associated liver disease — a condition that overlaps with but is distinct from MASH — is completing enrollment this quarter, adding yet another readout to track. The Phase 3 PERFORMA primary endpoint is projected for 2029. The AUD End-of-Phase 2 FDA meeting has not yet been scheduled. Pemvidutide is not available through compounding, does not circulate in wellness optimization culture, and is not the kind of peptide being discussed in longevity clinics or fitness forums. It is a serious clinical-stage drug asking questions about metabolic disease, liver damage, and addictive behavior that no single peptide has previously been positioned to answer. The questions are genuine. The answers are years away. Source trail before certainty.
Editorial boundary
What this page will not do
It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.